USP <800>: Hazardous Drug Handling Compliance
USP General Chapter <800> Hazardous Drugs — Handling in Healthcare Settings establishes standards for handling hazardous drugs (HDs) to minimise risk of exposure to healthcare personnel, patients and the environment.
In Short
- Layer 0 is the NIOSH HD List — the authoritative list of in-scope substances, updated periodically (current revision 2020, 2024 update in progress).
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings classifies drugs in three tables: Table 1 antineoplastic (cytotoxic and non-cytotoxic…
- Sterile HD compounding requires a Containment Primary Engineering Control (C-PEC) — typically a Class II Type B2 BSC or a CACI — externally vented; located in a…
Officially in effect since December 2019 (enforceable November 2023 after CMS deeming alignment). Scope: every entity that handles HDs on the NIOSH List of Hazardous Drugs — hospitals, clinics, pharmacies, physician offices, veterinary practices, home-care, 503A compounding pharmacies, 503B outsourcing facilities and manufacturers handling HD APIs. The Chapter intersects with USP <795> (non-sterile compounding, revised 2023), USP <797> (sterile compounding, revised 2023), OSHA HazCom (29 CFR 1910.1200) and state Boards of Pharmacy. NIOSH publishes and periodically updates the HD List in three groups: antineoplastic drugs (Group 1), non-antineoplastic drugs meeting one or more NIOSH criteria (Group 2), and drugs with reproductive effects (Group 3).
The USP <800> stack — Assessment of Risk, facility, controls, personnel
Layer 0 is the NIOSH HD List — the authoritative list of in-scope substances, updated periodically (current revision 2020, 2024 update in progress). Layer 1 is the Assessment of Risk (AoR) — for HDs other than antineoplastic dosage forms requiring manipulation, an entity may perform a documented AoR to determine alternative containment strategies; AoR cannot exclude antineoplastic dosage forms requiring any manipulation beyond counting/repackaging.
More on the USP <800> stack — Assessment of Risk, facility, controls, personnel
Layer 2 is facility design — Containment Primary Engineering Controls (C-PEC) in a Containment Secondary Engineering Control (C-SEC) with externally-vented negative-pressure room, 30 air changes per hour minimum for sterile HD compounding, ISO Class 5 in the C-PEC, dedicated storage with negative pressure and 12 ACH minimum. Layer 3 is environmental and personnel controls — PPE (chemo-rated gloves double-gloved, gown, eye/face protection, respirator for spills), closed system transfer devices (CSTDs) required for administration and recommended for compounding of antineoplastics, surface wipe sampling, deactivation/decontamination/cleaning. Layer 4 is personnel — competency training, periodic reassessment, medical surveillance and exposure response.
NIOSH HD List and Assessment of Risk
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings classifies drugs in three tables: Table 1 antineoplastic (cytotoxic and non-cytotoxic anticancer), Table 2 non-antineoplastic meeting at least one NIOSH HD criterion, Table 3 drugs primarily with reproductive effects. USP <800> requires that all Table 1 antineoplastic active pharmaceutical ingredients and antineoplastic dosage forms requiring manipulation (anything beyond counting tablets or repackaging) be handled with full <800> containment.
More on nIOSH HD List and Assessment of Risk
For Table 2 and 3, and for antineoplastic dosage forms not requiring manipulation, the entity may conduct an Assessment of Risk to define alternative containment strategies — the AoR documents drug type, dosage form, packaging, manipulation, exposure routes and risk-mitigation controls, and is reviewed at least every 12 months.
Facility engineering — C-PEC, C-SEC, pressure and air changes
Sterile HD compounding requires a Containment Primary Engineering Control (C-PEC) — typically a Class II Type B2 BSC or a CACI — externally vented; located in a Containment Secondary Engineering Control (C-SEC) ISO Class 7 buffer room with negative pressure relative to adjacent area (0.01-0.03 inches water column), 30 air changes per hour minimum, externally vented; with an anteroom (positive pressure to corridor, negative or positive to buffer per chapter requirements) for hand hygiene and garbing. Non-sterile HD compounding requires a C-PEC (Containment Ventilated Enclosure or Class I BSC) in a non-classified C-SEC with negative pressure, 12 ACH minimum, externally vented.
More on facility engineering — C-PEC, C-SEC, pressure and air changes
Storage of HDs requires a dedicated area with negative pressure to surroundings and 12 ACH minimum. Recirculation of HEPA-filtered air back to general HVAC is generally prohibited.
Personnel — PPE, training, medical surveillance
Personnel handling HDs must wear PPE per the chapter and the entity's risk assessment: chemo-rated gloves (ASTM D6978-rated) double-gloved when compounding, gown (ASTM-rated, single-use, fluid-resistant, back-closure), head/hair/shoe covers, eye and face protection where splash risk exists, NIOSH-approved respirator (N95 or higher; full-face for spills). Training and competency — initial training before handling, hands-on competency assessment, periodic reassessment (at least every 12 months).
More on personnel — PPE, training, medical surveillance
Medical surveillance program with baseline and periodic assessment for personnel routinely handling HDs (the OSHA-style program — not always implemented in practice but recommended in <800>). Exposure response procedure including spill kits, eye-wash availability and post-exposure protocol with documentation.
Environmental Wipe Sampling and Deactivation/Decontamination/Cleaning
USP <800> recommends environmental wipe sampling for HD surface contamination at least every 6 months, with results trending to identify control gaps. No federal action level is specified; commonly-referenced limits include 1 ng/cm² for cyclophosphamide as a control benchmark.
More on environmental Wipe Sampling and Deactivation/Decontamination/Cleaning
Deactivation/decontamination/cleaning (DDC) is a three-step process: deactivation with appropriate agent (commonly sodium hypochlorite followed by thiosulfate), decontamination to physically remove residual HD (water or appropriate solvent), cleaning with germicidal detergent. DDC sequence must be documented and validated; cleaning agents must be compatible with C-PEC manufacturer instructions.
Intersection with <795>, <797>, OSHA HazCom and state boards
USP <800> applies in addition to USP <795> for non-sterile HD compounding and USP <797> for sterile HD compounding. The 2023 revisions of <795> and <797> align with <800> facility requirements but each chapter retains distinct requirements (BUDs, environmental monitoring, garbing, training).
More on intersection with <795>, <797>, OSHA HazCom and state boards
OSHA HazCom (29 CFR 1910.1200) applies to all hazardous chemicals including HDs — SDS, labeling, HazCom plan and training are required. State Boards of Pharmacy enforce USP standards through pharmacy licensing and inspection; many states adopted <800> through state regulation independent of federal CMS deeming. CMS treats <800> as a Condition of Participation for Medicare-participating hospitals as of November 2023.
Practical readiness — building for USP <800>
Conduct and maintain a current Assessment of Risk for non-antineoplastic HDs and antineoplastic dosage forms not requiring manipulation. Validate facility design against <800> with current room certifications (semi-annual for sterile, annual for non-sterile).
More on practical readiness — building for USP <800>
Run the PPE programme with manufacturer testing data (ASTM D6978 chemo gloves, ASTM-rated gowns). Run competency training and document hands-on assessment. Establish wipe-sample programme with action levels and trending. Establish DDC SOP with cleaning-agent compatibility verification. Maintain spill response kits, eye-wash stations and post-exposure documentation. Track NIOSH HD List updates — additions trigger AoR and procedure updates.
Questions
Can we count antineoplastic tablets in a regular pharmacy?
Counting and repackaging final antineoplastic dosage forms (e.g., counting tablets into a vial) is considered manipulation. USP <800> requires that this occur in a C-PEC with full containment. The AoR cannot exclude antineoplastic dosage forms from <800> containment when any manipulation occurs. Many pharmacies move antineoplastic dispensing to a dedicated HD area.
Are CSTDs required for compounding antineoplastics?
USP <800> requires Closed System Transfer Devices for administration of antineoplastic HDs when the dosage form allows. CSTDs are recommended (not required) for compounding antineoplastics, but recommended practice strongly favours CSTD use during compounding to reduce surface contamination. Many institutions use CSTDs for both compounding and administration.
Does <800> apply to veterinary settings?
USP <800> is written for healthcare settings broadly. Many of the principles apply to veterinary practices handling HDs (chemotherapy for companion animals, hormonal preparations), and state veterinary boards increasingly reference <800>. AVMA guidance aligns with <800> principles for veterinary use.
How does <800> compliance interact with CMS?
CMS treats USP <800> compliance as part of pharmaceutical service Conditions of Participation for Medicare-participating hospitals from November 2023. Non-compliance can affect Medicare participation. State Boards of Pharmacy enforce through licensing. Joint Commission and DNV accreditation surveys assess <800> compliance against hospital pharmacy programmes.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
Keep reading
US DSCSA Enhanced Drug Distribution Security Readiness
FTC Made in USA Labels (16 CFR 323) and Endorsement Disclosures
21 CFR Part 211 Guide: Scope, Batch Controls and QCU Review
21 CFR 212 PET Drug cGMP Readiness: Production Evidence Guide
Extralabel Drug Use (21 CFR 530): Limits, Labelling and Compounding- NSF 173 & USP <2750> Readiness: Third-Party Supplement Certification